Automatic Membership Renewal
Now Available

Sign Up for Automatic Membership Renewal

- **Save time** — Lessen your to-do list
- **Go green** — Eliminate paper invoices and their impact on the environment
- **Uninterrupted membership** — Never miss an issue of *The Journal of Neuroscience* or any of your valuable member benefits
- **Bonus Day** — Ensure access to your choice of prime housing for the annual meeting before the opening of advance member registration
- **Support the field** — Know your dues enhance professional development initiatives, public outreach, advocacy, and more

Sign up through “My SfN” at SfN.org
Join us!

Drug Discovery Project Leader in Neuropsychiatry

We are looking for a highly-motivated scientific leader with skills in project management and the ability to translate emerging scientific knowledge on Proteinopathies into novel drug candidates for the improved treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

Working in the Neuropsychiatry Department, you will lead a dedicated project either derived from internal programs, or sourced from outside institutions. You will coordinate multidisciplinary work with internal and external partners from the phase of target validation through to the proposition of preclinical candidates.

Your mission, mirroring our “R and D” working spirit, will be articulated around the principles of Entrepreneurship, Collaboration, Performance and Communication.

Major requirements:

- Ph.D. and Post-Doc in Neuroscience: Expertise in the fields of Proteinopathies and Neurodegenerative disorders of the CNS.
- 2-5 years’ experience after your PhD, preferably involving a drug discovery-related position in a Biotech or Pharmaceutical company.
- Strong organizational skills and the ability to design and run a unique project.
- Excellent interpersonal relations and a well-developed sense of team-work.
- Perfectly fluent in English - French would be a plus.

Joining Servier means working in a stimulating environment and contributing to an innovative, research-based and people-oriented organization.

Servier is the leading French independent pharmaceutical company, located in 144 countries with 21,000 employees and a turnover in 2015 of about 4 billion euros.

25% of Servier’s annual turnover is reinvested in Research & Development, reflecting the company’s dedication to its mission of innovation and discovery for improved treatment of unmet medical needs.

Organized as a foundation, we guarantee our independence toward stock exchange market. Our founder Doctor Jacques Servier used to say: “a company is a group of human beings, so it has no price”.

Servier is well known for staff care, with particular attention to career evolution within the Group, and to an agreeable and productive working environment.

Together with international experts, for over 30 years we have been investing in programs to improve the control of neuropsychiatric and neurodegenerative diseases like Alzheimer’s, Parkinson’s, multiple sclerosis and depression.

Our Research Center in Neuropsychiatry is located near Paris, in Croissy-sur-Seine, France.

To apply or to acquire more details concerning the position, please contact geoffoy.bellet@servier.com - ref.117
Become part of the world’s largest organization of scientists and physicians devoted to understanding the brain and nervous system.

Join now and enjoy exclusive member benefits:

- Reduced fees and advanced registration for Neuroscience 2016
- Online subscription and reduced publication fees for JNeurosci
- Abstract submission eligibility for the annual meeting
- Networking and scientific discussion on Neuronline
- Free online access to the European Journal of Neuroscience
- Premium career services through NeuroJobs
- Also, by being part of SfN, your membership dues help fund programs and initiatives that support efforts across the field of neuroscience.
- And more!

Join now at SfN.org
STATEMENT OF OWNERSHIP, SOCIETY FOR NEUROSCIENCE


<table>
<thead>
<tr>
<th></th>
<th>Average No. of Copies each issue during preceding 12 months</th>
<th>Single issue nearest filing date</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Total No copies printed</td>
<td>209</td>
<td>154</td>
</tr>
<tr>
<td>B. Paid Circulation Mail</td>
<td>92</td>
<td>83</td>
</tr>
<tr>
<td>C. Total Paid Distribution</td>
<td>119</td>
<td>107</td>
</tr>
<tr>
<td>D. Free Distribution (including samples by Mail, Carrier or Other Means)</td>
<td>39</td>
<td>13</td>
</tr>
<tr>
<td>E. Total Distribution (Sum of C and D)</td>
<td>158</td>
<td>120</td>
</tr>
<tr>
<td>F. Office Use, left-over, unaccounted, spoiled after printing</td>
<td>50</td>
<td>34</td>
</tr>
<tr>
<td>G. Total (Sum of E and F – should equal net press run shown in A)</td>
<td>209</td>
<td>154</td>
</tr>
</tbody>
</table>

I certify that the statements made by me above are correct and complete. S. Rosenzweig
Submit Your Research

Committed to Excellence, Rigor, and Breadth

eNeuro has joined JNeurosci in the PubMed Central database.

Learn more at SfN.org